ANDA 211116, held by Crossmedika SA. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 211116 (Trazodone Hydrochloride), held by Crossmedika SA, was first approved by FDA on May 20, 2024, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2024 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 20, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters